Magazine
ENEWS
SUBSCRIBE
WEBINARS
PODCASTS
EBOOKS
Edit submissions
Press releases
Media kit
Innovation Awards
Home
Editors' (re)View
Welcome to Editors' (re)View, our editors’ weekly takes on things going on in the pharma world that deserve some extra consideration.
Articles
Editors' (re)View: McKinsey under fire for opioid crisis; Nexus gives up its generic plant
Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of April 21
Editors' (re)View: A new obesity startup; Schizophrenia treatment happenings
Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of April 15.
Editors' (re)View: Advancing mental health treatment; CMS proposes financial incentives for gene therapy access
Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of April 8
Editors' (re)View: ALS and drug approval criteria; Verve trial paused again
Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of April 1
Editors' (re)View: J&J can contest talc scientific evidence; SCOTUS mifepristone hearing met with skepticism
Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of March 25
News
Novo obesity drug reduces heart failure-related symptoms
Editors' (re)View: J&J cast-off anti-hypertensive wins approval; Orchard prices MLD therapy at $4.25M
Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of March 18
Editors' (re)View: FDA shares early AD industry guidance; WuXi-BIO breakup
Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of March 11
Editors' (re)View: Perrigo launches OTC birth control; Lilly takes aim at celebs
Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of March 4
Editors' (re)View: Probing pharma-sponsored testing; FDA approves Alvotech-Teva Humira biosim
Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of February 24
Editors' (re)View: Landmark approval for solid tumors; Relief for food allergy sufferers
Pharma Manufacturing editors Karen Langhauser and Andrea Corona comment on the notable happenings in the pharma industry from the week of February 19
Editors' (re)View: Humira's patent blip; Hope for pancreatic cancer
Pharma Manufacturing editors comment on the notable happenings in the pharma industry from the week of February 12
Editors' (re)View: Lilly weighs in on Novo deal; J&J drug brings immune disease hope
Pharma Manufacturing editors comment on the notable happenings in the pharma industry from the week of February 5
Editors' (re)View: CMS commits to improving CGT access; The Aduhelm exit
Pharma Manufacturing editors comment on the notable happenings in the pharma industry from the week of January 28
Editors' (re)View: Lilly's hearing loss win; Sandoz is open for business
Pharma Manufacturing editors comment on the notable happenings in the pharma industry from the week of Jan 22
Editors' (re)View: FTC wins another battle; Weight loss side effects
Pharma Manufacturing editors comment on the notable happenings in the pharma industry from the week of January 8
Load More Content